Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kentaro Yamazaki

Showing results (131-140 of 252) with videos related to

Pageof 26
Sort By:
International Journal of Clinical Oncology|March 11, 2010
Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysisTakeshi Sakamoto, Hirofumi Yasui, Narikazu Boku, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 5, 2010
Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatinRai Shimoyama, Hirofumi Yasui, Narikazu Boku, et al.
Investigational New Drugs|April 9, 2021
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancerHiroto Inoue, Akiko Todaka, Kentaro Yamazaki, et al.
The Oncologist|July 9, 2024
Impact of relative cisplatin dose to skeletal muscle mass on adverse events in patients with head and neck cancer undergoing chemoradiotherapySatoshi Suzuki, Tomoya Yokota, Akifumi Notsu, et al.
Cancer Chemotherapy and Pharmacology|August 28, 2016
Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancerTakeshi Kawakami, Nozomu Machida, Hirofumi Yasui, et al.
Cancer Chemotherapy and Pharmacology|January 11, 2015
A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancerKentaro Yamazaki, Hiroyuki Kuwano, Hitoshi Ojima, et al.
International Journal of Clinical Oncology|December 22, 2005
Small cell carcinoma of the esophagus responding to fourth-line chemotherapy with weekly paclitaxelMasaki Matsuoka, Narikazu Boku, Takayuki Yoshino, et al.
Cancer Medicine|February 19, 2022
The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective studyTakeshi Kawakami, Toshiki Masuishi, Yasuyuki Kawamoto, et al.
Investigational New Drugs|October 26, 2024
A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapySatoshi Hamauchi, Hirofumi Yasui, Tomoya Yokota, et al.
Investigational New Drugs|January 18, 2012
Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumorsToshiaki Takahashi, Narikazu Boku, Haruyasu Murakami, et al.
Pageof 26

Showing results (131-140 of 252) with videos related to

Sort By:
Pageof 26
International Journal of Clinical Oncology|March 11, 2010
Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysisTakeshi Sakamoto, Hirofumi Yasui, Narikazu Boku, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 5, 2010
Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatinRai Shimoyama, Hirofumi Yasui, Narikazu Boku, et al.
Investigational New Drugs|April 9, 2021
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancerHiroto Inoue, Akiko Todaka, Kentaro Yamazaki, et al.
The Oncologist|July 9, 2024
Impact of relative cisplatin dose to skeletal muscle mass on adverse events in patients with head and neck cancer undergoing chemoradiotherapySatoshi Suzuki, Tomoya Yokota, Akifumi Notsu, et al.
Cancer Chemotherapy and Pharmacology|August 28, 2016
Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancerTakeshi Kawakami, Nozomu Machida, Hirofumi Yasui, et al.
Cancer Chemotherapy and Pharmacology|January 11, 2015
A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancerKentaro Yamazaki, Hiroyuki Kuwano, Hitoshi Ojima, et al.
International Journal of Clinical Oncology|December 22, 2005
Small cell carcinoma of the esophagus responding to fourth-line chemotherapy with weekly paclitaxelMasaki Matsuoka, Narikazu Boku, Takayuki Yoshino, et al.
Cancer Medicine|February 19, 2022
The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective studyTakeshi Kawakami, Toshiki Masuishi, Yasuyuki Kawamoto, et al.
Investigational New Drugs|October 26, 2024
A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapySatoshi Hamauchi, Hirofumi Yasui, Tomoya Yokota, et al.
Investigational New Drugs|January 18, 2012
Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumorsToshiaki Takahashi, Narikazu Boku, Haruyasu Murakami, et al.
Pageof 26